Mantle Cell Lymphoma Market Analysis, Epidemiology, and Forecast 2034

Leading pharmaceutical organizations operating in the Mantle Cell Lymphoma sector comprise Bristol Myers Squibb, Eli Lilly, Kite Pharma, BeOne, Roche, Merck, Iksuda Therapeutics, NovalGen, PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi - ETS, PrECOG, LLC, Acerta Pharma, among others.

The Mantle Cell Lymphoma marketplace is projected to experience substantial growth driven by rising disease prevalence and enhanced awareness throughout the projection timeframe. Additionally, the introduction of numerous multi-phase Mantle Cell Lymphoma pipeline candidates will considerably transform the market landscape dynamics.

DelveInsight's comprehensive "Mantle Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034" analysis delivers extensive understanding of Mantle Cell Lymphoma, historical and projected epidemiology alongside market trends across the United States, EU5 nations (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Mantle Cell Lymphoma market analysis encompasses emerging therapeutic agents, present treatment methodologies, market share distribution of individual therapies, and current plus forecasted market dimensions from 2020 through 2034. It further assesses existing treatment protocols/algorithms, market growth factors and obstacles, and unmet clinical requirements to identify optimal opportunities and evaluate underlying market potential.

For comprehensive details about the Mantle Cell Lymphoma market perspective, drug adoption, treatment landscape and epidemiology patterns, Click here; Mantle Cell Lymphoma Market Insights

https://www.delveinsight.com/report-store/mantle-cell-lymphoma-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Essential Insights from the Mantle Cell Lymphoma Market Analysis:

• The Mantle Cell Lymphoma market dimension is expected to expand with substantial CAGR throughout the analysis timeframe (2020-2034).

• During November 2025, The FDA awarded priority review status to the new drug application (NDA) for sonrotoclax (BGB-11417) designed for managing adult patients diagnosed with relapsed or refractory mantle cell lymphoma (MCL) following prior BTK inhibitor therapy. The NDA draws support from outcomes of the Phase 1/2 BGB-11417-201 investigation (NCT05471843), which achieved its primary endpoint of overall response rate (ORR) evaluated by an independent review committee (IRC) and showed clinically significant responses in 125 adult patients with relapsed/refractory MCL previously exposed to BTK inhibitor treatment.

• During November 2025, The European Commission approved lisocabtagene maraleucel (liso-cel; Breyanzi) for managing adult patients diagnosed with relapsed or refractory mantle cell lymphoma (MCL) following at least two previous systemic treatment regimens, including a Bruton's tyrosine kinase (BTK) inhibitor, as announced in a Bristol Myers Squibb press statement.

• During November 2025, AstraZeneca initiated a Phase II investigation in Spain to evaluate the safety and efficacy of combining acalabrutinib with R-CHOP as initial treatment for patients diagnosed with mantle cell lymphoma (MCL).

• During November 2025, The H. Lee Moffitt Cancer Center and Research Institute commenced a Phase II clinical investigation for relapsed or refractory mantle cell lymphoma (R/R MCL) patients qualified to receive standard-of-care CD19 CAR T-cell therapy utilizing brexucabtagene autoleucel (brexu-cel).

• During June 2025, The FDA approved the tablet formulation of zanubrutinib for managing B-cell malignancies, including Mantle Cell Lymphoma, in patients who have received at least one prior treatment regimen.

• During May 2025, Based on findings from the phase 2 ECOG-ACRIN E1411 investigation (NCT01415752), incorporating bortezomib (Velcade) to bendamustine and rituximab (Rituxan; BR) as induction treatment did not result in enhanced 2-year progression-free survival (PFS) versus BR alone in patients diagnosed with mantle cell lymphoma (MCL). Nevertheless, Brad S. Kahl, MD, observed that the robust 2-year PFS attained with BR alone has created a strong platform for future progress in MCL management.

• During May 2025, Brad Kahl, MD, a professor of medicine, co-chair of the SCC Protocol Review and Monitoring Committee, and director of the Lymphoma Program at Washington University School of Medicine in St. Louis, emphasized the ongoing treatment obstacles in mantle cell lymphoma (MCL) and underscored the necessity of progressing therapeutic alternatives for diverse patient populations.

• During February 2025, The ROR1-targeted antibody-drug conjugate (ADC) zilovertamab vedotin (MK-2140) exhibited antitumor activity and an acceptable safety profile in extensively pretreated patients diagnosed with relapsed or refractory mantle cell lymphoma (MCL), according to results from cohort A of the phase 2 waveLINE-006 investigation (NCT05458297) presented at the 2024 ASH Annual Meeting.

• During December 2024, Galapagos NV revealed supplementary data from the continuing Phase I/II ATALANTA-1 investigation of its CD19 CAR T-cell therapy, GLPG5101. The findings, showcased in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, illustrate robust efficacy and a favorable safety profile in patients diagnosed with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). The majority of study participants received GLPG5101 as a fresh, fit, stem-like, early memory CD19 CAR T-cell therapy, achieving a median vein-to-vein duration of seven days.

• During June 2024, Roche disclosed the US FDA awarded Breakthrough Therapy Designation to Glofitamab for managing Mantle Cell Lymphoma.

• Numerous treatment alternatives are presently authorized for Mantle Cell Lymphoma, including BREYANZI (lisocabtagene maraleucel), JAYPIRCA (pirtobrutinib), TECARTUS (brexucabtagene autoleucel), BRUKINSA, among additional options.

• Encouraging forthcoming Mantle Cell Lymphoma therapeutic agents anticipated to generate significant advancement throughout the forecast timeframe comprise COLUMVI (glofitamab) by Roche, BGB-11417 (sonrotoclax) by BeOne, NVG-111 by NovalGen, among other investigational candidates.

• Mantle cell lymphoma (MCL) represents an uncommon variant of B-cell non-Hodgkin lymphoma (NHL), primarily affecting males beyond 60 years of age. It constitutes approximately 5% of all NHL diagnoses and typically initiates as an indolent condition, though it may evolve into a more aggressive variant over time.

• Mantle Cell Lymphoma is an uncommon and aggressive variant of B-cell non-Hodgkin lymphoma, manifesting at an incidence of approximately one diagnosis per 200,000 individuals annually. Its limited prevalence complicates early identification and presents challenges in recruiting participants for clinical investigations.

• Mantle Cell Lymphoma constitutes roughly 5% of all non-Hodgkin lymphoma diagnoses, classifying it as an uncommon subtype. Nevertheless, it maintains clinical significance because the condition often demonstrates aggressive behavior and sustained treatment responses prove challenging to achieve.

• The condition exhibits a marked male predominance, manifesting approximately three times more frequently in males than in females, a pattern documented across various geographic regions worldwide.

• The median diagnostic age typically spans from 60 to 70 years, with most patients receiving diagnosis during their late 60s. Mantle Cell Lymphoma predominantly impacts older adult populations, and the patient's age upon diagnosis can influence treatment selection and overall prognosis.

• Leading Mantle Cell Lymphoma Organizations: Bristol Myers Squibb, Eli Lilly, Kite Pharma, BeOne, Roche, Merck, Iksuda Therapeutics, NovalGen, PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi - ETS, PrECOG, LLC, Acerta Pharma, among others

• Primary Mantle Cell Lymphoma Therapeutic Agents: BREYANZI (lisocabtagene maraleucel), JAYPIRCA (pirtobrutinib), TECARTUS (brexucabtagene autoleucel), Sonrotoclax, COLUMVI (glofitamab), Zilovertamab Vedotin, IKS03, NVG-111, PEP07, LP-168, GLPG5101, Zamtocabtagene autoleucel, Glofitamab, Lenalidomide, Obinutuzumab, Pirtobrutinib, Ibrutinib, BGB-11417, Everolimus, Venetoclax, Ixazomib, Acalabrutinib, among others

Mantle Cell Lymphoma Disease Background

An uncommon variant of B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL) impacts one in 200,000 individuals annually. Approximately 5% of non-Hodgkin lymphomas represent MCL. The median diagnostic age for MCL ranges between 60 and 70 years, and males demonstrate higher susceptibility (3 to 1 ratio).

Access a complimentary sample for the Mantle Cell Lymphoma Market Analysis: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Mantle Cell Lymphoma Epidemiology Analysis

The Mantle Cell Lymphoma epidemiology segment delivers insights into historical, current, and projected epidemiology patterns across the seven major countries (7MM) from 2020 through 2034. It facilitates recognition of causes underlying current and forecasted patterns by examining multiple studies and perspectives of key opinion leaders. The epidemiology segment additionally provides comprehensive analysis of the diagnosed patient population and emerging trends.

Mantle Cell Lymphoma Epidemiology Classification:

The Mantle Cell Lymphoma market analysis presents epidemiological evaluation for the analysis period 2020-2034 across the 7MM categorized into:

• Total Prevalence of Mantle Cell Lymphoma

• Prevalent Cases of Mantle Cell Lymphoma by severity classification

• Gender-specific Prevalence of Mantle Cell Lymphoma

• Diagnosed Cases of Episodic and Chronic Mantle Cell Lymphoma

Access the analysis to comprehend which elements are influencing Mantle Cell Lymphoma epidemiology patterns @ Mantle Cell Lymphoma Epidemiological Insights

Mantle Cell Lymphoma Drug Adoption and Pipeline Activities

The drug adoption segment concentrates on the uptake velocity of potential therapeutic agents recently introduced in the Mantle Cell Lymphoma marketplace or anticipated to launch during the analysis period. The evaluation encompasses Mantle Cell Lymphoma market adoption by therapeutic agents, patient adoption by treatment modalities, and revenue of individual drugs.

Furthermore, the therapeutics evaluation segment facilitates understanding of drugs demonstrating the most accelerated adoption and underlying reasons for maximal utilization. Additionally, it compares therapeutic agents based on market penetration.

The analysis also encompasses the Mantle Cell Lymphoma Pipeline Development Activities. It delivers valuable insights regarding various therapeutic candidates across multiple phases and primary organizations engaged in developing targeted therapies. It additionally analyzes recent advancements including collaborations, acquisitions, mergers, licensing patent information, and other intelligence for emerging therapeutic agents.

Mantle Cell Lymphoma Therapeutic Agents and Leading Organizations

• BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb

• JAYPIRCA (pirtobrutinib): Eli Lilly

• TECARTUS (brexucabtagene autoleucel): Kite Pharma

• Sonrotoclax: BeOne

• COLUMVI (glofitamab): Roche

• Zilovertamab Vedotin: Merck

• IKS03: Iksuda Therapeutics

• NVG-111: NovalGen

• PEP07: PharmaEngine

• LP-168: Jiangsu Hansoh Pharmaceutical

• GLPG5101: Galapagos NV

• Zamtocabtagene autoleucel: Miltenyi Biomedicine

• Glofitamab: Roche

• Lenalidomide: Celgene

• Obinutuzumab: The Lymphoma Academic Research Org

• Pirtobrutinib: Loxo Oncology

• Ibrutinib: Janssen R&D

• BGB-11417: BeiGene

• Everolimus: Novartis

• Venetoclax: Fondazione Italiana Linfomi - ETS

• Ixazomib: PrECOG, LLC

• Acalabrutinib: Acerta Pharma

Explore additional information about therapeutic agents positioned to capture significant Mantle Cell Lymphoma market penetration @ Mantle Cell Lymphoma Medications

Mantle Cell Lymphoma Market Growth Factors

• Expanding prevalence of MCL and increased diagnosis resulting from enhanced screening and awareness initiatives.

• Progress in targeted therapeutic approaches, encompassing BTK inhibitors, CAR-T cell treatments, and combination protocols.

• Increasing implementation of personalized medicine and biomarker-guided treatment methodologies.

• Robust R&D pipeline featuring ongoing clinical investigations enhancing treatment alternatives and survival outcomes.

• Supportive regulatory environment, including fast-track and orphan drug designations accelerating approvals.

Mantle Cell Lymphoma Market Obstacles

• Elevated cost of advanced therapeutic approaches including CAR-T and targeted inhibitors, constraining accessibility.

• Limited curative alternatives and elevated relapse incidence despite treatment progress.

• Restricted patient population attributable to the uncommon nature of the condition, limiting commercial viability.

• Adverse reactions associated with systemic therapies influencing treatment adherence.

• Reimbursement obstacles in multiple regions decreasing therapy implementation.

• Complexity in treatment sequencing and absence of standardized long-term management protocols.

Coverage of the Mantle Cell Lymphoma Market Analysis

• Analysis Period: 2020-2034

• Geographic Coverage: Global

• Leading Mantle Cell Lymphoma Organizations: Bristol Myers Squibb, Eli Lilly, Kite Pharma, BeOne, Roche, Merck, Iksuda Therapeutics, NovalGen, PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi - ETS, PrECOG, LLC, Acerta Pharma, among others

• Primary Mantle Cell Lymphoma Therapeutic Agents: BREYANZI (lisocabtagene maraleucel), JAYPIRCA (pirtobrutinib), TECARTUS (brexucabtagene autoleucel), Sonrotoclax, COLUMVI (glofitamab), Zilovertamab Vedotin, IKS03, NVG-111, PEP07, LP-168, GLPG5101, Zamtocabtagene autoleucel, Glofitamab, Lenalidomide, Obinutuzumab, Pirtobrutinib, Ibrutinib, BGB-11417, Everolimus, Venetoclax, Ixazomib, Acalabrutinib, among others

• Mantle Cell Lymphoma Therapeutic Evaluation: Mantle Cell Lymphoma current commercialized and Mantle Cell Lymphoma investigational therapies

• Mantle Cell Lymphoma Market Dynamics: Mantle Cell Lymphoma market growth factors and Mantle Cell Lymphoma market obstacles

• Mantle Cell Lymphoma Competitive Intelligence Evaluation: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry methodologies

• Mantle Cell Lymphoma Unmet Requirements, KOL perspectives, Analyst perspectives, Mantle Cell Lymphoma Market Access and Reimbursement

For additional information about Mantle Cell Lymphoma management, visit @ Mantle Cell Lymphoma Treatment Landscape

Report Structure

1. Mantle Cell Lymphoma Market Analysis Introduction

2. Executive Summary for Mantle Cell Lymphoma

3. SWOT evaluation of Mantle Cell Lymphoma

4. Mantle Cell Lymphoma Patient Distribution (%) Overview at a Glance

5. Mantle Cell Lymphoma Market Overview at a Glance

6. Mantle Cell Lymphoma Disease Background and Overview

7. Mantle Cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Mantle Cell Lymphoma

9. Mantle Cell Lymphoma Current Treatment and Medical Practices

10. Mantle Cell Lymphoma Unmet Requirements

11. Mantle Cell Lymphoma Emerging Therapeutic Agents

12. Mantle Cell Lymphoma Market Perspective

13. Country-Wise Mantle Cell Lymphoma Market Evaluation (2020-2034)

14. Mantle Cell Lymphoma Market Access and Reimbursement of Therapeutic Agents

15. Mantle Cell Lymphoma Market Growth Factors

16. Mantle Cell Lymphoma Market Obstacles

17. Mantle Cell Lymphoma Appendix

18. Mantle Cell Lymphoma Analysis Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a prominent Healthcare Business Consultant and Market Research organization focused exclusively on life sciences. It supports pharmaceutical companies by delivering comprehensive end-to-end solutions to enhance their performance.It additionally provides Healthcare Consulting Services, which contribute to market evaluation to accelerate business expansion and overcome obstacles with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com